Comparison of GC-MS, HPLC-MS and SIFT-MS in conjunction with multivariate classification for the diagnosis of Crohn's disease in urine by Cauchi, M. et al.
 
 
Comparison of GC-MS, HPLC-MS and SIFT-MS in
conjunction with multivariate classification for the
diagnosis of Crohn's disease in urine
Cauchi, M.; Fowler, D. P.; Walton, C.; Turner, C.; Waring, Rosemary; Ramsden, David;
Hunter, J. O.; Teale, P.; Cole, Jeffrey; Bessant, C.
DOI:
10.1039/C5AY01322D
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Cauchi, M, Fowler, DP, Walton, C, Turner, C, Waring, RH, Ramsden, DB, Hunter, JO, Teale, P, Cole, JA &
Bessant, C 2015, 'Comparison of GC-MS, HPLC-MS and SIFT-MS in conjunction with multivariate classification
for the diagnosis of Crohn's disease in urine', Analytical Methods, vol. 7, no. 19, pp. 8379-8385.
https://doi.org/10.1039/C5AY01322D
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 10/12/2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Analytical
Methods
PAPER
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Se
pt
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
0/
12
/2
01
5 
14
:0
7:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View IssueComparison of GaSchool of Aerospace, Transport and Manu
Bedfordshire MK43 0AL, UK. E-mail: m.cauc
bSchool of Energy, Environment and A
Bedfordshire MK43 0AL, UK
cThe Department of Life, Health and Che
Keynes, MK7 6AA, UK
dSchool of Biosciences, University of Birming
eGastroenterology Research Unit, Addenbro
0QQ, UK
fLGC Ltd, Newmarket Rd, Fordham, Cambri
gSchool of Biological and Chemical Sciences
End Road, London E1 4NS, UK
† Electronic supplementary informa
10.1039/c5ay01322d
Cite this: Anal. Methods, 2015, 7, 8379
Received 21st May 2015
Accepted 30th August 2015
DOI: 10.1039/c5ay01322d
www.rsc.org/methods
This journal is © The Royal Society of CC-MS, HPLC-MS and SIFT-MS in
conjunction with multivariate classiﬁcation for the
diagnosis of Crohn's disease in urine†
M. Cauchi,*a D. P. Fowler,b C. Walton,b C. Turner,c R. H. Waring,d D. B. Ramsden,d
J. O. Hunter,e P. Teale,f J. A. Coled and C. Bessantg
The developed world has seen an alarming increase in the incidence of gastrointestinal diseases, among the
most common of which is Crohn's disease (CD) in the young. The current “gold standard” techniques for
diagnosis are often costly, time consuming, ineﬃcient, invasive, and oﬀer poor sensitivities and
speciﬁcities. This paper compares the performances of three hyphenated instrumental techniques that
have been suggested as rapid methods for the non-invasive diagnosis of CD from urine. These
techniques are gas chromatography-mass spectrometry (GC-MS), high performance liquid
chromatography-mass spectrometry (HPLC-MS) and selected ion ﬂow tube mass spectrometry (SIFT-
MS). Each of these techniques is followed by multivariate classiﬁcation to provide a diagnosis based on
the acquired data. The most promising results for potentially diagnosing CD was via HPLC-MS. An overall
classiﬁcation accuracy of 73% (74% speciﬁcity; 73% sensitivity) was achieved for diﬀerentiating CD from
healthy controls, statistically signiﬁcant at 95% conﬁdence.Introduction
The incidences of patients in the developed world being diag-
nosed with gastrointestinal diseases have been increasing in
recent years. This may be attributable to a combination of life-
style traits, particularly unhealthy diet involving foods high in
saturated fat, starch and sugar, and lack of fruit and vegetables
normally rich in anti-oxidants.1 This has led to an increased
interest in research into the causes, prevention and possible
cure of these diseases.2 Further to this are cases of food intol-
erance which could be due to abnormal fermentation processes
occurring within the gut3 or a drastic change in diet leading to
increased incidences of Crohn's disease.4
Crohn's disease (CD) is a debilitating inammatory bowel
disease (IBD) causing inammation of the mucosal lining in thefacturing (SATM), Craneld University,
hi@craneld.ac.uk
grifood (SEEA), Craneld University,
mical Sciences, Open University, Milton
ham, Birmingham B15 2TT, UK
oke's Hospital, Box 262, Cambridge CB2
dgeshire CB7 5WW, UK
, Queen Mary University of London, Mile
tion (ESI) available. See DOI:
hemistry 2015gut.5–7 It is known that CD can aﬀect any part of the gastroin-
testinal tract, whereas ulcerative colitis (UC) – another IBD –
typically only aﬀects the large colon. The presenting symptoms
of CD and UC (chiey abdominal pain and diarrhoea) are
similar making diﬀerential diagnosis of these two conditions
challenging. This is very important because the treatment
required is diﬀerent.8 There have been occasions in which a
patient deemed to be suﬀering from UC is later diagnosed with
CD. This is in conjunction with the discovery of new therapeutic
agents employed to treat IBD.9,10
Colonoscopy and sigmoidoscopy are the current “gold
standard” methods of diagnosing CD (and UC).11,12 Sigmoidos-
copy permits a direct 5–20 minute examination of the lining of
the rectum and the lower part of the colon by using a bre-optic
scope attached to a camera enabling the examiner to observe
the lining for any irregularities. Colonoscopy makes use of a
probe of greater length which is able to extend up to the ileum.13
The duration of the procedure can be 30 minutes in which it is
necessary for the patient to be sedated. This tends to be a more
accurate diagnostic technique than sigmoidoscopy.8,11 The two
techniques are however highly invasive and expensive to
perform.
An alternative approach is the determination of chemical
biomarkers such as faecal calprotectin.14–17 However, the diag-
nostic performance of these tests is limited, which has led to the
investigation of analytical approaches to the non-invasive
diagnosis and monitoring of these conditions.18 More recently,
analytical techniques incorporating mass spectrometric
methods have been used to capture metabolic proles ofAnal. Methods, 2015, 7, 8379–8385 | 8379
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View Article Onlineclinical samples. These can either analyse metabolites in solu-
tion19 or those in the vapour phase, so called volatile organic
compounds (VOCs). These have advantages in that analysis can
be non-invasive if urine, faeces, breath and some other uids
are analysed, reducing the need for invasive procedures which
are uncomfortable and costly.
High performance liquid chromatography coupled with
mass spectrometry (HPLC-MS) is routinely employed in pro-
teomics,20 and gas chromatography mass spectrometry (GC-MS)
techniques have been employed for many years for the detec-
tion of metabolites21 including the possible diagnosis of
gastrointestinal diseases.22,23 HPLC-MS is also being employed
in the study of metabolomics data such as the determination of
the changes in the human urinary metabolome aer the
consumption of certain nuts, e.g. almonds,24,25 and the study of
the age and strain-related diﬀerences in the Zucker rat.26,27 It
has also been used in conjunction with proton nuclear
magnetic resonance (1H NMR) for the analysis of biouid
samples.28–30
The relatively new technique of selected ion ow tube mass
spectrometry (SIFT-MS) is also being employed in metab-
olomics.31–36 Rapid and quantitative analysis of VOCs can be
achieved using SIFT-MS. This employs a fast ow tube to study
the reaction of precursor ions with sample molecules in gas or
vapour form. The ow tube technology, along with the quanti-
tative mass spectrometry, allows selected precursor ions (H3O
+,
NO+, and O2
+) to react in turn with the sample molecules to
produce product ions through chemical ionisation (CI). These
product ions are separated in a downstream quadrupole and are
then detected and quantied. A kinetic database is used to
quantify the concentrations of various molecules present in the
sample. The particular precursor ions are chosen because they
have slow reaction rates with the components of air, but react
quickly with trace gases and vapours that may be used in
research. This technology, unlike most CI techniques, is able to
use all three reagents rapidly in turn on the same instrument.32
SIFT-MS is being widely employed for the real time analysis of
volatile compounds originating from biological systems in
medical applications33 and clinical diagnosis.34 A key advantage
of SIFT-MS is the ability to distinguish between diﬀerent
isomers via the use of the three precursor ions mentioned
previously.37
These analytical techniques all have the capability of
producing large amounts of data about metabolites present,
and therefore sophisticated techniques are needed in analysis.
Multivariate classication is a pattern recognition technique
which determines which samples belong to a designated class.21
One approach is partial least squares discriminant analysis
(PLS-DA)38,39 and is termed a supervised method leading to the
separation of samples into diﬀerent classes, for example
healthy and diseased. Although there exist more advanced
techniques such as support vector machines40 and articial
neural networks,41 PLS-DA permits the direct identication of
statistically signicant features that may be related to potential
biomarkers by visual inspection of the PLS loadings.39,42 A
recent study reported the use of GC-MS in conjunction with PLS-
DA for the diagnosis of gastrointestinal diseases including8380 | Anal. Methods, 2015, 7, 8379–8385Crohn's disease in a series of matrices (faeces, breath, blood
and urine).43 This study found that only CD could be diagnosed
in the presence of the other diseases and healthy controls. This
was achieved using faecal material. Very good accuracy was also
attained for CD by analysing urine, but the sensitivity was below
50% and thus of no diagnostic benet.
In looking at diagnostic or screening tests, the ease of
sample acquisition and use is an important consideration.
Faecal samples are generally harder to collect and process, not
least of which is due to the subjects' reluctance to provide
samples. Blood is also occasionally problematic due to the
invasive nature of the sampling, and the discomfort caused to
patients by venepuncture. For this reason, and the ease of
collection and storage, urine is considered to be a better matrix
to use, which is the reason why it was investigated in this study.
The present article describes the application of multivariate
classication to GC-MS, HPLC-MS and SIFT-MS data acquired
from the same urine samples which were employed in our
previous paper.43 This was carried out in order to determine
whether the greater sensitivity and overall accuracy was ach-
ieved compared with the results obtained using GC-MS data, the
overall objective being to distinguish patients suﬀering from
CD from those with IBS and UC and from healthy individuals.
Experimental
Reagents
Unless otherwise stated, analytical grade reagents and solvents
were employed.
Sampling
Selection of candidates. Volunteers were recruited from
patients attending the Gastroenterology Department at Adden-
brooke's Hospital (Cambridge, UK). There were an initial total
of 57 candidates of which 18 were diagnosed with Crohn's
disease (CD), 8 with ulcerative colitis (UC), 18 with irritable
bowel syndrome (IBS) and 13 who were deemed healthy. Each
candidate gave oral and written consent. They were issued with
a urine sample container bearing their individual code. This
was to ensure patient condentiality in accordance with the
Data Protection Act (1998).
The study had been ethically approved by the National
Research Ethics Service in Leeds in July 2007 (07/Q1205/39).
Instrumental measurements
GC-MS. The samples were aspired into thermal desorption
tubes and 50 ng of deuterated (D8)-toluene were added subse-
quently as an internal standard (IS). These tubes were loaded on
to an automated thermal desorption gas chromatography mass
spectrometer (ATD-GC-MS) and analysed. A more detailed
account of the instrumental parameters and conditions are
provided elsewhere.43
HPLC-MS. Samples were prepared using a simple dilution
approach (1 in 10) in water containing deuterated (D6)-caﬀeine
(100 ngml1) as IS. This was executed by placing 900 ml of water/
IS in a standard LC-MS injection vial using a repeating pipetteThis journal is © The Royal Society of Chemistry 2015
Paper Analytical Methods
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
Se
pt
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
0/
12
/2
01
5 
14
:0
7:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineand adding 100 ml of sample (aspirated from the top of the
sample tube without mixing to avoid picking up solids). The LC
vials were then capped and vortex-mixed. All sample prepara-
tion and analysis was carried out in a single process. Samples
were analysed using a 7 minute LC-MS run in positive ion mode
on an Orbitrap Discovery system running at 30 000 resolution.
The injection volume was 10 ml. A more detailed account of the
instrumental parameters and conditions are listed in Table SM1
of the ESI.†
SIFT-MS. Urine (2.5 ml) was placed in a sample bag made
from 65mm diameter Nalophan NA tubing (Kalle UK). The bags
were sealed and then lled with hydrocarbon-free air and
equilibrated in an incubator at 40 C to generate a vapour
headspace. One end of each sample bag was connected via a
Swagelok tting directly to the SIFT-MS capillary inlet for
analysis of the urine headspace, and VOCs in the sample were
analysed in each sample aer equilibration. The SIFT-MS was a
Prole 3 model manufactured by Instrument Science (UK).
The sample VOCs react with one of three precursor ions
(H3O
+, NO+ or O2
+) to generate product ions, which are then
separated via a quadrupole and counted (in counts per second)
at the detector. Thus the data obtained are in the form of counts
per second determined over a 30 second period at each mass to
charge ratio (m/z), from m/z 10 to m/z 140. The data thus
obtained represent the amount of product ion formed using
each of the three precursor ions. Using this instrument, whole
volatile proles of samples may be generated very rapidly,
oﬀering real time instantaneous results as opposed to GC-MS
and HPLC-MS which can only oﬀer “snapshots” of instances in
a particular time and space.Data pre-processing
GC-MS. The raw GC-MS les produced by the ATD-GC-MS
instrument were imported into MATLAB (R2011a, MathWorks
Inc., USA) in the NetCDF (.CDF) format. During the importation
of each le, which corresponded to one sample, the intensity
values pertaining to the retention times andmass-to-charge (m/z)
ratios were normalised against the deuterated (D8)-toluene, and
then summed across the m/z values to produce a data matrix
whose order was the number of samples and the number of
retention time values. This eﬀectively forms a matrix of total ion
count (TIC) chromatograms. Exploratory data analysis tech-
niques were employed to identify any specic trends and sample
outliers. These were principal components analysis (PCA)44
in conjunction with Hotelling's T2 statistic45 and hierarchicalTable 1 Comparison of the optimum PLS-DA classiﬁcation results for CD
combination of sample matrix and disease is determined from the perm
Instrument % CCa (%) SPECa (%)
GC-MS 52.3 62.8
HPLC-MS 73.3 73.7
SIFT-MS 48.2 55.7
a % CC: The overall correctly classied; SPEC: Specicity; SENS: Sensitivit
This journal is © The Royal Society of Chemistry 2015cluster analysis (HCA).46 This is necessary because the presence
of outlying samples will aﬀect the performance of the chro-
matographic peak alignment detailed below. No samples were
identied to be outlying.
Correlation optimised warping (COW)47 was employed to
align the chromatograms. This has the advantage of requiring
minimum user input especially as the two main parameters
(segment and slack) are determined automatically. A segment
contains a xed number of retention time ranges which contain
peaks to be shied. The extremity of the shiing is determined
by the slack. A reference chromatogram must rst be deter-
mined via a number of options such as the mean, median,
maximum or the correlation coeﬃcients. It is also possible to
employ a PCA loading (typically PC1) as a reference chromato-
gram.48 The latter was employed here. Aer the segment and
slack parameters were automatically determined, they were
employed to align the respective chromatograms within the
data matrix.
HPLC-MS. The raw HPLC-MS data les were converted to
ASCII text format (.MLT) by the HPLC-MS soware (MassTransit
by Palisade). The contents of the text le were a column con-
taining the total ion counts (TICs), a column containing the
retention times, and a data matrix containing the single ion
counts (SICs) ranging from m/z 80 to m/z 850. The text le was
imported into MATLAB in its entirety. The single ion count (SIC)
chromatogram for deuterated caﬀeine was extracted at the
mass-charge (m/z) value of 201 in conjunction with the naturally
occurring internal standard of creatinine49 at the m/z value of
114, and all intensity values in each sample matrix were nor-
malised against them. The normalised SICs in each sample
were summed to form a total ion count (TIC) chromatogram for
each sample. All samples were combined into a data matrix in
which the dimensions were the number of samples by the
number of retention time values.
Principal components analysis (PCA) and correlation opti-
mised warping (COW) was employed as for GC-MS.
SIFT-MS. The raw SIFT-MS data les (three for each sample
resulting from the three precursor ions employed) were pro-
cessed by “SIFT-MS Soware” (v4.300.231.1396, © Patrik Spanel,
1996–2006), combined and exported to an Excel le, which was
imported into MATLAB. Data pre-processing involved normal-
isation of the m/z values against the relevant precursor ions (e.g.
normalised against m/z 19, the H3O
+ precursor), followed by
removal of the precursor and associated ions prior to subsequent
analysis; these were: 19, 21, 30, 32, 34, 37, 39, 48, 55, 57, 66, 73, 75
and 91. Lastly, any m/z values where zero abundance wasversus healthy controls in urine. The signiﬁcance of the result for each
utation testing results using a z-test
SENSa (%) AUROCb
p value from
z-test (a ¼ 0.05)
34.7 0.45 0.502
73.1 0.79 <0.001
42.6 0.43 0.093
y. b Area under the receiver operating characteristic (AUROC) curve.
Anal. Methods, 2015, 7, 8379–8385 | 8381
Table 2 Comparison of the optimum PLS-DA classiﬁcation results for Cr
The signiﬁcance of the result for each combination of samplematrix and d
Instrument % CCa (%) SPECa (%)
GC-MS 70.8 72.8
HPLC-MS 68.2 75.7
SIFT-MS 62.6 77.9
a % CC: The overall correctly classied; SPEC: Specicity; SENS: Sensitivit
Fig. 1 Distributions of the overall percentage classiﬁed for the 150
evaluations (light grey) and after randomised assignation of classes for
the 300 permutations (dark grey) for CD versus control in urine. % CC
denotes the percent correctly classiﬁed.
8382 | Anal. Methods, 2015, 7, 8379–8385
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View Article Onlinerecorded in all samples were removed. PCA was performed as
described for GC-MS leading to the identication of one outlying
sample – a UC sample, which was removed due to having rela-
tively very high abundances compared to all other samples.Data analysis
Multivariate classication. Multivariate classication was
carried out in MATLAB also using functions from the PLS
Toolbox (v3.5, Eigenvector Research Inc., USA). Partial least
squares discriminant analysis (PLS-DA)38 was employed to
construct models relating the acquired data for each sample to
the sample class. It employs the SIMPLS algorithm50 to reduce
the response proles (chromatograms for GC-MS and HPLC-
MS, or mass spectra for SIFT-MS) into latent variables which
capture the maximum amount of covariance. This is achieved
using a two-step nested process which simultaneously opti-
mises and evaluates the respective models via a heuristic
bootstrapping approach in which leave-one-out cross-validation
(LOO-CV) is employed for model optimisation. Bootstrapping is
used to get meaningful performance metrics. This is described
below.
Validation and performance metrics. Validation is usually
performed to ensure that the classication models generated
are robust in terms of their ability to generalise to newly
acquired data.51Our approach has three nested stages which are
an evaluation stage, an inner optimisation stage and an outer
optimisation stage. The evaluation stage tests the performance
of the optimal model suggested by the two optimisation stages.
In this work 150 evaluations were performed. The average
overall accuracy, specicity, and sensitivity over all evaluations
are calculated. The area under the receiver operating charac-
teristic (AUROC) curve is also determined from the sensitivity
and specicity values via the trapezoid rule.52 ROC curves are
employed in the medical eld to determine whether a diag-
nostic test is suﬃcient in deducing whether an individual is
healthy or has a particular disease/condition.53
The overall success of classication is determined in
conjunction with the specicity and sensitivity. Specicity
determines how well the healthy (control) samples were classi-
ed whilst sensitivity determines how well the target case
(diseased) samples were classied.
Permutation testing. A permutation test was performed
in order to determine whether the performance of the classi-
cation models were statistically signicant or due to chance.51,54
This was achieved by the random assignation of the target casesohn's disease versus healthy controls and other disease cases in urine.
isease is determined from the permutation testing results using a z-test
SENSa (%) AUROCb
p value
from z-test (a ¼ 0.05)
65.9 0.78 <0.001
54.6 0.61 <0.001
30.2 0.52 <0.001
y. b Area under the receiver operating characteristic (AUROC) curve.
This journal is © The Royal Society of Chemistry 2015
Fig. 2 Distribution of the overall percentage classiﬁed for the 150
evaluations (light grey) and after randomised assignation of classes for
the 300 permutations (dark grey) for CD versus control and other
disease cases in urine. % CC denotes the percent correctly classiﬁed.
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View Article Online(e.g. healthy controls and CD) to each sample while maintaining
the number of healthy and diseased samples actually observed,
followed by classication using the heuristic bootstrapping
approach described previously. This was repeated 300 times
which ensured that a smooth distribution was attained. The
distribution of the permutations (n1 ¼ 300) was compared
visually against the distribution of the evaluations (n2 ¼ 150),
and the statistical two-sampled two-tailed z-test was calculated
(a ¼ 0.05) at the 95% condence limit in order to determine the
statistical signicance.55
Results and discussion
Table 1 summarises the results attained for the classication of
Crohn's disease against the healthy control in the urine sample
matrix for GC-MS, HPLC-MS and SIFT-MS.
Fig. 1 displays the permutation test51 results comparing both
the distribution of the permutations and the evaluations.
Table 1 and Fig. 1 show that, using urine as the analyte
matrix, HPLC-MS in conjunction with multivariate classica-
tion is the best of the three methods for diﬀerentiating CD
patients from healthy controls.
This is supported by the comparison of the means of the two
distributions in which the calculated z-values were statistically
signicant for HPLC-MS but insignicant for both GC-MS and
SIFT-MS.
In clinical practice, the presenting symptoms are similar for
a range of conditions. The data analysis was therefore repeated
in order to diﬀerentiate CD in the presence of other diseases
(IBS and UC) in addition to healthy controls. The results are
summarized in Table 2. Fig. 2 shows the permutation test
results for CD versus the healthy controls and other disease
states comparing both the distribution of the permutations and
the evaluations.
These results show that the discrimination of CD against
healthy controls and other target cases is more challenging than
separating CD from healthy controls only. This is evident in the
sensitivities reported in Table 2 for HPLC-MS and SIFT-MS. By
comparison, increased sensitivity was observed in the GC-MS
data with overall classication accuracy (% CC) over 70% being
attained. The specicities shown in Table 2 exceed 70%. This
may be attributed to the imbalance of the respective datasets,
resulting from combining the data from the other diseases (IBS
and UC) with those of the healthy controls to form one “healthy”
dataset. As a consequence the PLS-DA model is better trained
to recognize the “healthy” class. However the sensitivity for
GC-MS reported earlier in Table 1 was very low (35%), sug-
gesting failure to distinguish the target case (CD) from the
healthy controls. To investigate this phenomenon, the
misclassication of IBS, UC and healthy controls as CD was
investigated (Table 3).
Table 3 suggests that for GC-MS, 30% of control samples
were misclassied as CD samples, whilst 26% and 25% of IBS
and UC samples respectively were misclassied as CD. This
explains why the sensitivity of 35% was attained for CD versus
control only (Table 1), which was due to the diﬃculty in GC-MS
distinguishing between controls and CD.This journal is © The Royal Society of Chemistry 2015This is also apparent for SIFT-MS, because 25% of control
samples were misclassied as CD, and only 30% of CD samples
were correctly classied. In contrast, fewer control samples were
misclassied as CD via HPLC-MS. Furthermore, 26% of UC
samples were misclassied as CD, conrming the diﬃculty in
distinguishing between CD and UC.9,10
Further interrogation of the loadings extracted from the PLS-DA
model pertaining to the CD versus control dataset for HPLC-MS,
resulted in a number of compounds being identied via theAnal. Methods, 2015, 7, 8379–8385 | 8383
Table 3 Illustration of the ability of the models developed for CD vs.
healthy controls and other disease cases for each instrumental tech-
nique to classify the samples. Numerical values in columns represent
the percentage of samples (pertaining to each case) classiﬁed as CD
Case
Instrument
GC-MS HPLC-MS SIFT-MS
CD 66 55 30
IBS 26 25 22
UC 25 26 20
CTRL 30 23 25
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acin-C, 3-(3-hydroxyphenyl) propionic acid, chalcomoracin,
dimethyl azelate, nonanedioic acid dimethyl ester and 9-hydroxy-
imino-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido(1,2-A) pyrimi-
dine-3-carboxylic acid ethyl ester (“HMOTPPCAEE”). However,
moracin-C and chalcomoracin were found to be antibacterial
compounds and could be as a result of drugs taken by CD and IBS
suﬀerers.56 Moracin-C was also found in IBS versus control. Of
great interest, 3-(3-hydroxyphenyl) propionic acid, dimethyl aze-
late, nonanedioic acid dimethyl ester and “HMOTPPCAEE” could
be potential biomarkers for CD (in urine via HPLC-MS) since no
occurrences were identied in the control, IBS and UC samples.
Propionic acid had also been observed to be statistically
signicant in the faecal samples of patients presenting with
CD57 which suggests that this could be a key metabolite since
observed in both urine and faecal samples. There had also been
increases in the concentrations of alcohol and ester derivatives
of indole and some short-chain fatty acids such as 3-methyl
butanoic acid in CD compared to UC and IBS.57
Furthermore, a key problem is in diﬀerentiating between
Crohn's disease and ulcerative colitis. They present similarly
but have diﬀerent treatments. These metabolic proling tech-
niques should be used in conjunction with clinical symptoms.
Other common conditions of the gastro-intestinal tract such as
IBS may also be diﬀerentiated43,57 but generally have less severe
symptoms. Moreover, many gastrointestinal diseases have
similar symptoms such as pain, diarrhoea and weight loss, but
very diﬀerent pathology which may be reected in separate
biomarkers which are thus of potential diagnostic value. Lastly,
a study in 2013 further illustrated that 25% of cases of CD do
not get a diagnosis until two years have elapsed58 therefore
highlighting the need for a more rapid diagnosis.Conclusions
The comparison of the three instrumental techniques for the
diagnosis of Crohn's disease (CD) using urine as the analyte
matrix indicated that HPLC-MS was the best for distinguishing
CD suﬀerers from healthy controls. Nevertheless when IBS and
UC patients were included into the subject matrix together with
healthy controls, GC-MS appeared to be the best method.
However, the misclassication of the IBS, UC and healthy
controls was taken into consideration (Table 3), it is possible that8384 | Anal. Methods, 2015, 7, 8379–8385HPLC-MS is superior. SIFT-MS and GC-MS analyses were not
suﬃciently accurate, with unacceptably low sensitivities. These
methods analyse VOCs, whereas HPLC-MS analyses metabolites
in solution. The results obtained using HPLC-MS imply that the
metabolites in solution are better indicators of CD than the
volatile compounds present in urine headspace. Previous work
has shown that VOCs in the headspace of faecal samples may be
used in diﬀerentiating CD fromUC and other IBDs,43,57 but use of
urine headspace is less eﬃcient as a means of classication.
The typical accuracy of the “gold-standard method” of colo-
noscopy at the time of writing was 79%. Though the overall
classication accuracies reported in this work did not exceed
this value (e.g. 73% via HPLC-MS for CD vs. healthy control) it
does suggest that urine could become a suitable matrix for
the non-invasive diagnosis of CD. The gold standard for
all gastrointestinal diseases remains endoscopy and the histo-
logical examination of tissue biopsies. Detection of specic
biomarkers may help focus accurately the investigations
required saving both time and expense.
This manuscript covered the potential for using this
combination of analytical instrumentation with multivariate
statistics for disease diagnosis. Further work would concentrate
on validating this technology, and then the diagnostic potential
would be in rolling this approach out in clinics, where it is oen
diﬃcult to diagnose Crohn's disease except via endoscopy or
sigmoidoscopy.
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